SDI and CSD announce launch of oncology therapeutic market research service

SDI and Cegedim Strategic Data (CSD) announced today that they will jointly launch a new market research service that tracks selling activities in the oncology therapeutic market. The Oncology Selling Audit will be released in January 2011; 2 years of history will be available for reporting and analysis.

“This partnership will benefit from CSD's global experience in Promotion Audits and allow for more in-depth analysis of sales and marketing strategies for all cancer treatments.”

With a robust panel of medical and radiation oncologists and hematologists/oncologists, the monthly service will provide nationally projected measures of personal selling in the oncology market, including competitive corporate calls, details, messages, and promotional spending. The service will permit analysis by tumor type, staging, and modalities.

"The Oncology Selling Audit continues to extend SDI's Promotional Audit Suite" notes Andrew Kress, CEO of SDI. "SDI continues to be a leading company that tracks and reports on virtually all forms of biopharmaceutical promotion including personal, non-personal, and consumer channels. This service additionally complements SDI's ability to provide real-time insights on the oncology disease and therapeutic marketplace through our other core data assets."

SDI's Promotional Audit Suite includes services that measure detailing, sampling, events, journal advertising, ePromotion, sales force sizes, and direct-to-consumer advertising.

CSD has Promotion Databases in 39 countries including the USA which also cover the above metrics.

"We are pleased to be partnering with SDI to bring this key service to the marketplace. This launch reaffirms the commitment to innovation that both organizations bring to healthcare measurement," says Bruno Lempernesse, Chief Operating Officer Sales and Marketing of Cegedim Strategic Data. "This partnership will benefit from CSD's global experience in Promotion Audits and allow for more in-depth analysis of sales and marketing strategies for all cancer treatments."